High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

By Levita K. Hidayat, D. Hsu, R. Quist, K. Shriner, A. Wong-Beringer. Archives of Internal Medicine, 2006

888 citations recorded by the source corpus.

Subfields: Infectious Diseases, Pharmacology

View Paper: https://www.semanticscholar.org/paper/84ec13b1e414a67e3d2aabeccc0e89842a47c0a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. D. Levine
2. Robert S. Daum
3. S. Cosgrove
4. J. Dalovisio
5. Henry F. Chambers
6. W. Craig
7. M. Rybak
8. J. Rotschafer

In Pharmacology

1. J. Dalovisio
2. W. Craig
3. M. Rybak
4. D. Levine
5. J. Rotschafer
6. M. Billeter
7. R. Moellering
8. B. Lomaestro

Citations in the corpus

• Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. (2008, background): “[26], who studied the efficacy of high vancomycin trough serum concentration ( 15 mg/mL) in a cohort of 95 patients with MRSA infection according to the MIC (!2 mg/mL vs.”
• Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “Higher vancomycin doses and trough concentrations may be associated with increased nephrotoxicity [263, 311, 315, 316] and high-frequency hearing loss in older patients [317].”
• Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications (2010, background): “This has been driven partly by studies demonstrating poorer outcomes for vancomycin treatment of MRSA infections with higher vancomycin MICs, even when these MICs are within the susceptible range (112, 184, 298, 332).”
• Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin (2008, background): “Within the past 5 years, multiple reports have described MRSA strains with vancomycin MICs at the high end of the CLSI susceptibility range (MICs of 2 mg/liter) (6, 18, 22).”
• Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. (2019, background): “Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”